OBJECTIVE: To identify disparities in the management of colon and rectal cancer across Europe by assessing population-based information from 12 European cancer registries (CR) participating in EUROCARE, together with additional information obtained from individual clinical records. METHODS AND PATIENTS: We considered five indicators: (a) resection with curative intent; (b) post-operative mortality; (c) proportion of stage II/III colon cancer cases given adjuvant chemotherapy; (d) proportion of rectal cancer cases receiving radiotherapy; and (e) proportion of curative intent resections with 12 or more lymph nodes examined. RESULTS: A total of 6 871 colorectal cancer patients, diagnosed between 1996-1998, were examined. Overall 71% of patients received resection with curative intent, range 44-86% by CR; 46% of stage III colon cancer cases (range 24-73% by CR) and 22% of stage II cases (not then recommended) received adjuvant chemotherapy; 12% of rectal cancer cases received adjuvant radiotherapy, range < or =2% in five CRs to >51% in two CRs. For only 29% of curative intent resections were 12 or more lymph nodes examined. CONCLUSIONS: This study reveals that, although most patients received surgery with curative intent, disparities in treatment for colorectal cancer across Europe in the late 1990s were unexpectedly large, with many patients not receiving treatments indicated by published clinical trials. Consensus guidelines for CRC management are now becoming available and should be adopted across Europe. It is hoped that dissemination of guidelines will improve the use of scientifically proven treatments for the disease, but this should be monitored by further population-based studies.
OBJECTIVE: To identify disparities in the management of colon and rectal cancer across Europe by assessing population-based information from 12 European cancer registries (CR) participating in EUROCARE, together with additional information obtained from individual clinical records. METHODS AND PATIENTS: We considered five indicators: (a) resection with curative intent; (b) post-operative mortality; (c) proportion of stage II/III colon cancer cases given adjuvant chemotherapy; (d) proportion of rectal cancer cases receiving radiotherapy; and (e) proportion of curative intent resections with 12 or more lymph nodes examined. RESULTS: A total of 6 871 colorectal cancerpatients, diagnosed between 1996-1998, were examined. Overall 71% of patients received resection with curative intent, range 44-86% by CR; 46% of stage III colon cancer cases (range 24-73% by CR) and 22% of stage II cases (not then recommended) received adjuvant chemotherapy; 12% of rectal cancer cases received adjuvant radiotherapy, range < or =2% in five CRs to >51% in two CRs. For only 29% of curative intent resections were 12 or more lymph nodes examined. CONCLUSIONS: This study reveals that, although most patients received surgery with curative intent, disparities in treatment for colorectal cancer across Europe in the late 1990s were unexpectedly large, with many patients not receiving treatments indicated by published clinical trials. Consensus guidelines for CRC management are now becoming available and should be adopted across Europe. It is hoped that dissemination of guidelines will improve the use of scientifically proven treatments for the disease, but this should be monitored by further population-based studies.
Authors: Joseph Lipscomb; K Robin Yabroff; Mark C Hornbrook; Anna Gigli; Silvia Francisci; Murray Krahn; Gemma Gatta; Annalisa Trama; Debra P Ritzwoller; Isabelle Durand-Zaleski; Ramzi Salloum; Neetu Chawla; Catia Angiolini; Emanuele Crocetti; Francesco Giusti; Stefano Guzzinati; Maura Mezzetti; Guido Miccinesi; Angela Mariotto Journal: J Natl Cancer Inst Monogr Date: 2013
Authors: Taryn E Hassinger; J Hunter Mehaffey; Allison N Martin; Kristine Bauer-Nilsen; Florence E Turrentine; Robert H Thiele; Bethany M Sarosiek; Matthew J Reilley; Sook C Hoang; Charles M Friel; Traci L Hedrick Journal: Dis Colon Rectum Date: 2019-11 Impact factor: 4.585
Authors: Federico Mazzotti; Alessandro Cucchetti; Yvette H M Claassen; Amanda C R K Bos; Esther Bastiaannet; Giorgio Ercolani; Jan Willem T Dekker Journal: World J Surg Date: 2019-08 Impact factor: 3.352
Authors: Anna Gigli; Joan L Warren; K Robin Yabroff; Silvia Francisci; Margaret Stedman; Stefano Guzzinati; Francesco Giusti; Guido Miccinesi; Emanuele Crocetti; Catia Angiolini; Angela Mariotto Journal: J Natl Cancer Inst Monogr Date: 2013
Authors: M P Coleman; D Forman; H Bryant; J Butler; B Rachet; C Maringe; U Nur; E Tracey; M Coory; J Hatcher; C E McGahan; D Turner; L Marrett; M L Gjerstorff; T B Johannesen; J Adolfsson; M Lambe; G Lawrence; D Meechan; E J Morris; R Middleton; J Steward; M A Richards Journal: Lancet Date: 2010-12-21 Impact factor: 79.321
Authors: O Dejardin; B Rachet; E Morris; V Bouvier; V Jooste; R Haynes; E G Coombes; D Forman; A P Jones; A M Bouvier; G Launoy Journal: Br J Cancer Date: 2013-02-07 Impact factor: 7.640
Authors: Claudia Allemani; Bernard Rachet; Hannah K Weir; Lisa C Richardson; Côme Lepage; Jean Faivre; Gemma Gatta; Riccardo Capocaccia; Milena Sant; Paolo Baili; Claudio Lombardo; Tiiu Aareleid; Eva Ardanaz; Magdalena Bielska-Lasota; Susan Bolick; Rosemary Cress; Marloes Elferink; John P Fulton; Jaume Galceran; Stanislaw Gózdz; Timo Hakulinen; Maja Primic-Zakelj; Jadwiga Rachtan; Chakameh Safaei Diba; Maria-José Sánchez; Maria J Schymura; Tiefu Shen; Giovanna Tagliabue; Rosario Tumino; Marina Vercelli; Holly J Wolf; Xiao-Cheng Wu; Michel P Coleman Journal: BMJ Open Date: 2013-09-10 Impact factor: 2.692
Authors: Jun Yin; Shaheenah Dawood; Romain Cohen; Jeff Meyers; John Zalcberg; Takayuki Yoshino; Matthew Seymour; Tim Maughan; Leonard Saltz; Eric Van Cutsem; Alan Venook; Hans-Joachim Schmoll; Richard Goldberg; Paulo Hoff; J Randolph Hecht; Herbert Hurwitz; Cornelis Punt; Eduard Diaz Rubio; Miriam Koopman; Chiara Cremolini; Volker Heinemann; Christophe Tournigard; Carsten Bokemeyer; Charles Fuchs; Niall Tebbutt; John Souglakos; Jean-Yves Doulliard; Fairooz Kabbinavar; Benoist Chibaudel; Aimery de Gramont; Qian Shi; Axel Grothey; Richard Adams Journal: Ther Adv Med Oncol Date: 2021-06-30 Impact factor: 8.168